Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

SHANGHAIandHONG KONG,Sept. 19, 2025/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced thatit will release the latest preclinical data of ATG-201 (CD19 x CD3 TCE) in Poster Presentations at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place fromOctober 24th to October 29thinChicago, IL,the United States.

AnTenGager^TM is Antengene's proprietary TCE 2.0 platform featuring"2+1"bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability acrossautoimmune diseases, solid tumors and hematological malignancies indications. ATG-201 is a novel"2+1"CD19-targeted T-cell engager developed on the AnTenGager^TMTCE platform for the treatment of autoimmune diseases.ATG-201 is poised to enter clinical development in Q4 2025.

Details of the Poster Presentations:

ATG-201（CD19 x CD3 TCE）

Title:ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

Abstract Number:0001

Session: (0001–0018) B Cell Biology& Targets in Autoimmune& Inflammatory Disease Poster I

Date:Sunday, October 26

Time:10:30 AM - 12:30 PM (Central Time)

           00:30 AM -02:30 AM,October 27(Beijing Time)

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring"2+1"bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. andAsia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland ofChina, Taiwan China,Hong Kong China, Macau China,South Korea,Singapore,Malaysia,Thailand,IndonesiaandAustralia, and has been included in the national insurance schemes in five of these markets (Mainland ofChina, Taiwan China,Australia,South KoreaandSingapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year endedDecember 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 

Donald Lung

E-mail:Donald.Lung@antengene.com 

Mobile: +86 18420672158

PR Contacts:

Peter Qian

E-mail:Peter.Qian@antengene.com

Mobile: +86 13062747000

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/antengene-to-present-latest-preclinical-results-from-atg-201-cd19xcd3-tce-at-acr-2025-302561366.html

SOURCE Antengene Corporation Limited